Not a home run, but first base: GSK unwraps PhII data on hepatitis B treatment in pursuit of ‘functional cure’
At the annual Liver Meeting on Tuesday, GSK unveiled results from a Phase II trial on its hepatitis B treatment, which it said earlier this year could “lead to a functional cure” for the liver infection.
In 457 patients treated with GSK’s bepirovirsen, 26 had undetectable levels of hepatitis B 24 weeks after treatment — measured by the amount of hepatitis B surface antigen and viral DNA. That amounts to about 6% of all patients, according to the study published in NEJM, but results varied widely between groups of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.